View our Exclusive report on Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.
Technavio has announced its latest market research report titled Coronavirus Test Kits Market in North America by End-user and Geography - Forecast and Analysis 2021-2025
The report on the Coronavirus test kits market in North America provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
In addition, the report also provides an up-to-date analysis regarding the current global market scenario and overall market environment. The market is driven by the regional outbreak of coronavirus and product innovations
/PRNewswire/ Technavio s latest market research report estimates the coronavirus test kits market in Europe to register a decremental growth of USD 4.61.
NEW YORK, April 30, 2021 /PRNewswire/
Technavio s latest market research report estimates the coronavirus test kits market in Europe to register a decremental growth of USD 4.61 billion at a CAGR of almost (28)% during 2021-2025. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
- Advertisement -
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. 3D Biomedicine Science and Technology Co. Ltd., Abbott Laboratories, BGI Genomics Co. Ltd., bioMerieux SA, Co-Diagnostics Inc., Danaher Corp., F. Hoffmann-La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., QIAGEN NV, and Thermo Fisher Scientific Inc. are some of the major market participants. Increasing government funding and the rising focus on preventing the spread of the COVID-19 pandemic will offer immense growth opportunities. To leverage the current opportunities, market vendor
Co-Diagnostics says its CoSara joint venture in India garnering media attention as it combats coronavirus surge
In particular, the Indian media have noted the extraordinary efforts of a CoSara team of six women who have increased capacity from roughly 8,000 coronavirus PCR tests per day a year ago to around 40,000 per day now In April 2020, CoSara, a joint venture with Synbiotics, became the first company headquartered in India to get a license to manufacture coronavirus test kits
Co-Diagnostics Inc (NASDAQ:CODX) has noted that its Indian manufacturing facility, CoSara Diagnostics Pvt Ltd, has garnered media attention for its actions to provide much-needed coronavirus (COVID-19) diagnostics as a wave of infections has led to the world s worst outbreak since the pandemic began.
Co-Diagnostics says Logix Smart COVID-19 Test performance validated by Australian researchers in peer-reviewed publication
A paper published in the Journal of Medical Microbiology utilizes the company s Logix Smart COVID-19 Test Kit in rapidly deployable mobile molecular diagnostics Co-Diagnostics CEO Dwight Egan said the results of the independent peer-reviewed paper further establishes the robustness, versatility, and quality of our Logix Smart COVID-19 diagnostic
Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company with a patented platform for the development of diagnostic tests, has revealed that its Logix Smart COVID-19 Test Kit was used by Australian researchers to demonstrate rapidly deployable mobile molecular diagnostics support for remote locations, with the peer-reviewed results published in the ‘Journal of Medical Microbiology.’